256 related articles for article (PubMed ID: 25280884)
1. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
[TBL] [Abstract][Full Text] [Related]
2. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
[TBL] [Abstract][Full Text] [Related]
3. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
4. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
[TBL] [Abstract][Full Text] [Related]
5. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
[TBL] [Abstract][Full Text] [Related]
6. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances in the study of accelerated blood clearance phenomenon of PEGylated liposomes].
Xu H; Wang KQ; Huang WW; Deng YH; Chen DW
Yao Xue Xue Bao; 2010 Jun; 45(6):677-83. PubMed ID: 20939173
[TBL] [Abstract][Full Text] [Related]
8. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
[TBL] [Abstract][Full Text] [Related]
9. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection.
Laverman P; Carstens MG; Boerman OC; Dams ET; Oyen WJ; van Rooijen N; Corstens FH; Storm G
J Pharmacol Exp Ther; 2001 Aug; 298(2):607-12. PubMed ID: 11454922
[TBL] [Abstract][Full Text] [Related]
12. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection.
Xu H; Ye F; Hu M; Yin P; Zhang W; Li Y; Yu X; Deng Y
Drug Deliv; 2015; 22(5):598-607. PubMed ID: 24524364
[TBL] [Abstract][Full Text] [Related]
13. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Wang X; Ishida T; Kiwada H
J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
[TBL] [Abstract][Full Text] [Related]
14. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
15. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.
Ishida T; Ichihara M; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060
[TBL] [Abstract][Full Text] [Related]
16. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
[TBL] [Abstract][Full Text] [Related]
17. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
[TBL] [Abstract][Full Text] [Related]
18. Impact of Anti-PEG IgM Induced via the Topical Application of a Cosmetic Product Containing PEG Derivatives on the Antitumor Effects of PEGylated Liposomal Antitumor Drug Formulations in Mice.
Gaballa SA; Shimizu T; Takata H; Ando H; Ibrahim M; Emam SE; Amorim Matsuo NC; Kim Y; Naguib YW; Mady FM; Khaled KA; Ishida T
Mol Pharm; 2024 Feb; 21(2):622-632. PubMed ID: 38273445
[TBL] [Abstract][Full Text] [Related]
19. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H
J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.
Cabanes A; Tzemach D; Goren D; Horowitz AT; Gabizon A
Clin Cancer Res; 1998 Feb; 4(2):499-505. PubMed ID: 9516942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]